68000-92-0 Usage
Description
Farnesyl cysteine, also known as S-farnesyl-L-cysteine, is a unique organic compound characterized by the presence of a farnesyl group attached to the L-cysteine molecule. FARNESYL CYSTEINE features C2C double bonds at the 2and 6-positions, both having (E)-configuration. Farnesyl cysteine plays a significant role in various biological processes and has potential applications in different industries due to its unique structure and properties.
Uses
Used in Pharmaceutical Industry:
Farnesyl cysteine is used as a key intermediate in the synthesis of various biologically active compounds, including drugs targeting specific signaling pathways. Its unique structure allows it to interact with cellular components, making it a valuable building block for the development of new therapeutic agents.
Used in Biochemical Research:
In the field of biochemical research, farnesyl cysteine serves as an important tool for studying the role of prenylation, a post-translational modification process that plays a crucial role in protein function and localization. Researchers use farnesyl cysteine to investigate the mechanisms of prenylation and its implications in various diseases, including cancer and neurodegenerative disorders.
Used in Cosmetic Industry:
Farnesyl cysteine has potential applications in the cosmetic industry due to its ability to modulate cellular processes and improve skin health. It can be used as an active ingredient in anti-aging products, where it may help to promote collagen production, reduce the appearance of fine lines and wrinkles, and maintain skin elasticity.
Used in Agricultural Industry:
In agriculture, farnesyl cysteine may be utilized as a component in the development of novel plant growth regulators or as a signaling molecule to enhance crop yield and resistance to various stressors. Its unique structure and properties make it a promising candidate for improving agricultural practices and crop management.
Check Digit Verification of cas no
The CAS Registry Mumber 68000-92-0 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 6,8,0,0 and 0 respectively; the second part has 2 digits, 9 and 2 respectively.
Calculate Digit Verification of CAS Registry Number 68000-92:
(7*6)+(6*8)+(5*0)+(4*0)+(3*0)+(2*9)+(1*2)=110
110 % 10 = 0
So 68000-92-0 is a valid CAS Registry Number.
InChI:InChI=1/C18H31NO2S/c1-14(2)7-5-8-15(3)9-6-10-16(4)11-12-22-13-17(19)18(20)21/h7,9,11,17H,5-6,8,10,12-13,19H2,1-4H3,(H,20,21)/b15-9+,16-11+/t17-/m0/s1
68000-92-0Relevant articles and documents
Synthetic optimization and mapk pathway activation anticancer mechanism of polyisoprenylated cysteinyl amide inhibitors
Tawfeeq, Nada,Jin, Yonghao,Lamango, Nazarius S.
, (2021/11/19)
Abnormalities of the MAPK pathway play vital roles in cancer initiation and progression. RAS GTPases that are key upstream mediators of the pathway are mutated in 30% of human cancers. Polyisoprenylated cysteinyl amide inhibitors (PCAIs) were designed as potential targeted therapies against the RAS-driven cancers. The current study reports on the optimization of the PCAIs and the determination of their mechanisms of action in KRAS-mutant cancer cells. They display ClogP values ranging from 3.01 to 6.35, suppressing the viabilities of KRAS-mutant MDA-MB-231, A549, MIA PaCa-2, and NCI-H1299 cells in 2D and 3D cultures with EC50 values of 2.2 to 6.8, 2.2 to 7.6, 2.3 to 6.5 and 5.0 to 14 μM, respectively. When A549 cells were treated with the PCAIs, NSL-YHJ-2-27, for 48 h, no significant difference was observed in the levels of total or phosphorylated B-and C-Raf proteins. However, at 5 μM, it stimulated the phosphorylation of MEK1/2, ERK1/2, and p90RSK by 84%, 59%, and 160%, respectively, relative to controls. A non-farnesylated analog, NSL-YHJ-2-62, did not elicit similar effects. These data reveal that effects on the RAS-MAPK signaling axis most likely contribute to the anticancer effects of the PCAIs, possibly through the proapoptotic isoforms of p90RSK. The PCAIs may thus have the potential to serve the unmet therapeutic needs of patients with aberrant hyperactive G-protein signaling.
Efficient S-alkylation of cysteine in the presence of 1,1,3,3- tetramethylguanidine
W?ostowski, Marek,Czarnocka, Sylwia,MacIejewski, Piotr
experimental part, p. 5977 - 5979 (2010/11/21)
The synthesis of S-alkylated cysteine derivatives was carried out successfully in the presence of 1,1,3,3-tetramethylguanidine. Alkylation proceeded in high yields on unprotected amino acids and peptides containing a sulfhydryl group.
INHIBITORS OF ISOPRENYLCYSTEINE CARBOXYL METHYLTRANSFERASE
-
Page/Page column 29-31, (2008/06/13)
The present invention relates, in general, to isoprenylcysteine carboxyl methyltransferase (Icmt) and, in particular, to inhibitors of Icmt and to methods of disease treatment using same.
